ClinicalTrials.gg
CompletedNCT02561156Updated Mar 3, 2021Results posted

TAK-653 Escalating Single and Multiple Dose Study in Healthy Participants

A Phase 1 interventional study of TAK-653 Placebo and TAK-653 in Depressive Disorder, sponsored by Neurocrine Biosciences. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-03.

Sponsored by Neurocrine Biosciences · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 42 studies in Depressive Disorder with a site in United Kingdom — 4 open to participants now, 4 under way, 2 of them phase 3. Depressive Disorder · United Kingdom.

Enrollment
13th of 34
88 · median 58
Started
2015
with 1 other
Phase 1
11 of 42
none open now
Registered
18th of 42
by date

Among the 42 studies in Depressive Disorder with a site in United Kingdom, this one is the 13th largest by enrollment of the 34 interventional ones that give a count, is one of 2 that started in 2015, is one of 11 in phase 1, and was the 18th registered.

Depressive Disorder

855 studies on the registry are indexed under Depressive Disorder; 159 are open to participants now.

Browse Depressive Disorder studies →

Open to participants now

4 of the 42 studies in Depressive Disorder with a site in United Kingdom are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 116 Depressive Disorder studies recruiting now, 44 (38%) set no upper age limit and 66 (57%) stop at 75 or younger; 24 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Depressive Disorder with a site in United Kingdom, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of TAK-653 when administered as single and multiple oral doses at escalating dose levels in healthy participants.

Read the detailed description

The drug being tested in this study is called TAK-653. TAK-653 is being tested to treat people who have depression. This study will look at the tolerability and PK of TAK-653 in healthy participants.

The study may enroll up to 112 participants and each cohort will enroll 8 participants. This study consists of 2 parts: Part 1- single rising dose (SRD) consisting of at least 6 cohorts and Part 2- single rising dose and multiple rising dose (SRD/MRD) consisting of at least 5 cohorts. Additional cohorts may be added depending on the emerging safety and PK data. Participants will be randomly assigned (by chance, like flipping a coin) within each cohort to receive TAK-653 or placebo which will remain undisclosed to the participants and study doctor during the study (unless there is an urgent medical need). Participants enrolled in Cohort 1 to 5 of Part 1 will receive TAK-653 0.3 mg, 1.0 mg, 3.0 mg, 5.0 mg and 9.0 mg or TAK-653 placebo-matching tablet. Subsequent dose escalation in Part-1, from Cohort 6 onward will occur after the full availability of safety, tolerability, PK, and PD data from preceding cohorts. Participants in Part-2 Cohorts 1 to 3 will receive TAK-653 0.3 mg, 1.0 mg and 3.0 mg respectively. Dose for Part 2, from Cohort 4 onward will be based on review of safety, tolerability, and available PK and PD data from previous cohorts. All participants will be asked to take the drug at the same time each day on Day 1 for Part 1 and Day 1 and Days 6 to 18 in Part 2.

This single-center trial will be conducted in the United Kingdom. The overall time to participate in this study is approximately 14 days for Part 1 and 31 days for Part 2. Participants will be admitted to the clinic for 6 days in Part 1 and 22 days in Part 2. Participants will be followed up 14 days after last dose of study drug for a follow-up assessment.

03

Conditions studied

  • Depressive Disorder

Browse trials for

Keywords

  • Drug therapy
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Is capable of understanding and complying with protocol requirements.
  2. Signs and dates a written, form and any required privacy authorization prior to the initiation of any study procedures including requesting that a participant fasts for any laboratory evaluations.
  3. Weighs at least 45 kilogram (kg) and has a (BMI) between 18.0 and 30.0 kilogram per square meter (kg/m\^2), inclusive at Screening.
  4. Male participant who is nonsterilized and sexually active with a female partner of agrees to use adequate from signing of informed consent throughout the duration of the study and for 90 days after 5 half-lives have elapsed since last dose of study drug. This should be interpreted as 90 days from the Follow-up Call/Visit unless data indicates otherwise.
  5. Female participant of childbearing potential who is sexually active with a nonsterilized male partner agrees to routinely use highly effective contraception with low user dependency from signing of informed consent, throughout the duration of the study, and for 30 days after 5 half-lives have elapsed since the last dose of study drug. This should be interpreted as 30 days from the Follow-up Call/Visit unless data indicates otherwise.

Exclusion criteria

Exclusion Criteria:

  1. Has received any compound within 90 days prior to the first dose of study drug.
  2. Is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in the conduct of this study (example, spouse, parent, child, sibling) or may consent under duress.
  3. Has any illness, such as cardiovascular, neurologic, pulmonary, hepatic, renal, metabolic, gastrointestinal, urologic, immunologic, endocrine, or psychiatric disease or disorder, or other abnormality, which may affect safety, increase risk of seizure or lower the seizure threshold, or potentially confound the study results. It is the responsibility of the investigator to assess the clinical significance; however, consultation with the Takeda Medical Monitor may be warranted.
  4. Has a known to any component of the formulation of TAK-653.
  5. Has taken any excluded medication, supplements, or food products during the time periods.
  6. Is pregnant or lactating or intending to become pregnant before, during, or within 30 days after 5 half-lives have elapsed since the last dose of study drug (30 days from the Follow-up Call/Visit unless available data indicates otherwise); or intending to donate ova during such time period.
  7. If male, intends to donate sperm during the course of this study or within 90 days after 5 half-lives have elapsed since the last dose of study drug. This should be interpreted as 90 days from the Follow-up Call/Visit unless data indicates otherwise.
  8. Has had previous episodes of seizures or convulsion (lifetime), including absence seizure and febrile convulsion.
  9. Participant or any immediate family member has a history of epilepsy (including febrile convulsions).
  10. Has a history of neurological abnormalities including abnormal EEG at screening or brain injury including traumatic injury, perinatal cerebropathy and postnatal brain damage, blood-brain barrier abnormality, and angioma cavernous.
  11. Has a history of cerebral arteriosclerosis.
  12. Has a condition that can potentially reduce drug clearance (example, renal or hepatic insufficiency).
  13. Has current or recent (within 6 months) gastrointestinal disease that would be expected to influence the absorption of drugs (that is, a history of malabsorption, any surgical intervention known to impact absorption [example, bariatric surgery or bowel resection], esophageal reflux, peptic ulcer disease, erosive esophagitis, or frequent [more than once per week] occurrence of heartburn).
  14. Has a history of cancer, except basal cell carcinoma which has been in remission for at least 5 years prior to Check-in (Day 1).
  15. Has a positive test result for surface antigen (HBsAg), virus (HCV) antibody, or a known history of (HIV) infection at Screening.
  16. Has poor peripheral venous access.
  17. Has a positive urine/blood result for drugs of abuse (defined as any illicit drug use) at Screening or Check-in (Day -1).
  18. Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 1 year prior to Screening or is unwilling to agree to abstain from alcohol and drugs throughout the study.
  19. Has used nicotine-containing products (including but not limited to cigarettes, pipes, cigars, chewing tobacco, nicotine patch, or nicotine gum) within 28 days prior to Check-in Day -1. Cotinine test is positive at Screening or Check-in (Day -1).
  20. Has donated or lost 450 milliliter (mL) or more of his or her blood volume (including plasmapheresis), or had a transfusion of any blood product within 90 days prior to first dose of study drug.
  21. Has a Screening or Check-in (Day -1) abnormal (clinically significant [CS]) . Entry of any participant with an abnormal (not clinically significant [NCS]) ECG must be approved, and documented by signature of the principal investigator or medically qualified subinvestigator. In the case of a corrected using Fridericia's formula (QTcF) interval greater than (>) 450 millisecond (msec) or >480 msec (participants with Bundle Branch Block) or PR outside the range of 120 to 220 msec, assessment may be repeated once for eligibility determination at the Screening Visit and/or Check-in (Day -1) Visit.
  22. Has a supine blood pressure outside the ranges of greater than or equal to (>=) 90 to less than or equal to (\<=)140 millimeter of mercury (mmHg) for systolic and >= 50 to \<= 90 mm Hg for diastolic. If out of range, assessment may be repeated once for eligibility determination at the Screening Visit and/or Check-in (Day -1).
  23. Has a resting heart rate outside the range of 50 to 90 bpm (not on ECGs). If out of range, the assessment may be repeated once for eligibility determination at the Screening Visit and/or Check-in (Day -1).
  24. Has abnormal Screening or Check-in (Day -1) laboratory values that suggest a clinically significant underlying disease or participant has the following lab abnormalities: (ALT) and/or Aspartate aminotransferase (AST) >1.5 (ULN).
  25. Has a risk of suicide per the C-SSRS (a score of 4 or 5 on ideation or any suicidal behavior) or according to the investigator's clinical judgment, has made a suicide attempt in the previous 6 months, or has a history of deliberate self-harm in the past 6 months.

Additional exclusion criteria for CSF collection in Cohort 3 in Part 2:

  1. Has had CSF collected within 6 months prior to Check-in (Day -1).
  2. Has a known hypersensitivity to the anesthetic or its derivatives used during CSF collection or any medication used to prepare the area of lumbar puncture.
  3. Has any skin condition, abnormality of the lumbar spine, medical or surgical condition that would preclude lumbar puncture (example, coagulopathy, local or systemic infection, left ventricular outflow obstruction, aortic stenosis, raised intracranial pressure, previous back surgery).
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
88 participants (actual)

Study arms

  • Experimental
    Part 1 Cohort 1: TAK-653 0.3 mg

    TAK-653 0.3 milligram (mg), tablet, orally, once on Day 1 or TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours.

    Drug: TAK-653 Placebo · Drug: TAK-653

  • Experimental
    Part 1 Cohort 2: TAK-653 1.0 mg

    TAK-653 1.0 mg, tablet, orally, once on Day 1 or TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours.

    Drug: TAK-653 Placebo · Drug: TAK-653

  • Experimental
    Part 1 Cohort 3: TAK-653 3.0 mg

    TAK-653 3.0 mg, tablet, orally, once on Day 1 or TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours.

    Drug: TAK-653 Placebo · Drug: TAK-653

  • Experimental
    Part 1 Cohort 4: TAK-653 5.0 mg

    TAK-653 5.0 mg, tablet, orally, once on Day 1 or TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours.

    Drug: TAK-653 Placebo · Drug: TAK-653

  • Experimental
    Part 1 Cohort 5: TAK-653 9.0 mg

    TAK-653 9.0 mg, tablet, orally, once on Day 1 or TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours.

    Drug: TAK-653 Placebo · Drug: TAK-653

  • Experimental
    Part 1 Cohort 6: TAK- 653 18 mg

    TAK-653 18 mg, tablet, orally, once on Day 1 or TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours. Dose escalation to be decided (TBD) based on safety, tolerability, and available PK and pharmacodynamics (PD) data from previous cohorts.

    Drug: TAK-653 Placebo · Drug: TAK-653

  • Experimental
    Part 1 Additional Cohorts: TAK- 653 Placebo

    TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours. Dose escalation TBD based on safety, tolerability, and available PK and PD data from previous cohorts.

    Drug: TAK-653 Placebo · Drug: TAK-653

  • Experimental
    Part 2 Cohort 1: TAK-653 0.3 mg

    TAK-653 0.3 mg, tablet, orally, once on Day 1, and once daily (QD) from Days 6 to 18 or placebo-matching tablet, orally, once on Day 1 and QD from Days 6 to 18.

    Drug: TAK-653 Placebo · Drug: TAK-653

  • Experimental
    Part 2 Cohort 2: TAK-653 1.0 mg

    TAK-653 1.0 mg, tablet, orally, once on Day 1, and QD from Days 6 to 18 or placebo-matching tablet, orally, once on Day 1 and QD from Days 6 to 18.

    Drug: TAK-653 Placebo · Drug: TAK-653

  • Experimental
    Part 2 Cohort 3: TAK-653 3.0 mg

    TAK-653 3.0 mg, tablet, orally, once on Day 1, and QD from Days 6 to 18 or placebo-matching tablet, orally, once on Day 1 and QD from Days 6 to 18.

    Drug: TAK-653 Placebo · Drug: TAK-653

  • Experimental
    Part 2 Cohort 4: TAK-653 6 mg

    TAK-653 6 mg, tablet, orally, once on Day 1, and QD from Days 6 to 18 or placebo-matching tablet, orally, once on Day 1 and QD from Days 6 to 18. Dose escalation TBD based on safety, tolerability, and available PK and PD data from previous cohorts.

    Drug: TAK-653 Placebo · Drug: TAK-653

  • Experimental
    Part 2 Cohort 5: TAK-653 9 mg

    TAK-653 9 mg, tablet, orally, once on Day 1, and QD from Days 6 to 18 or placebo-matching tablet, orally, once on Day 1 and QD from Days 6 to 18. Dose escalation TBD based on safety, tolerability, and available PK and PD data from previous cohorts.

    Drug: TAK-653 Placebo · Drug: TAK-653

  • Experimental
    Part 2 Additional Cohorts: TAK-653 Placebo

    TAK-653 placebo-matching tablet, orally, once on Day 1 and QD from Days 6 to 18. Dose escalation TBD based on safety, tolerability, and available PK and PD data from previous cohorts.

    Drug: TAK-653 Placebo · Drug: TAK-653

Interventions

  • DrugTAK-653 Placebo

    TAK-653 placebo-matching tablets.

  • TAK-653 tablets.

06

What researchers measure

Primary outcomes

  1. Part 1: Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE)

    Time frame: Baseline up to Day 14

  2. Part 2: Percentage of Participants Who Experience at Least One TEAE

    Time frame: Baseline up to Day 31

  3. Part 1: Percentage of Participants Who Discontinued the Treatment Due to an Adverse Event (AE)

    Time frame: Baseline up to Day 14

  4. Part 2: Percentage of Participants Who Discontinued the Treatment Due to an AE

    Time frame: Baseline up to Day 31

  5. Part 1: Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Postdose

    Time frame: Cohort 1-5: Baseline up to Day 7; Cohort 6: Baseline up to Day 8

  6. Part 2: Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Postdose

    Time frame: Baseline up to Day 8

  7. Part 1: Percentage of Participants Who Meet the Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Postdose

    Time frame: Cohort 1-5: Baseline up to Day 7; Cohort 6: Baseline up to Day 8

  8. Part 2: Percentage of Participants Who Meet the Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Postdose

    Time frame: Baseline up to Day 21

  9. Part 1: Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Electrocardiogram (ECG) at Least Once Postdose

    Time frame: Cohort 1-5: Baseline up to Day 7; Cohort 6: Baseline up to Day 8

  10. Part 2: Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety ECG at Least Once Postdose

    Time frame: Baseline up to Day 8

  11. Part 1: Percentage of Participants Who Experience Clinically Significant Abnormal Changes in Safety Electroencephalogram (EEG) Measurements at Least Once Postdose

    Time frame: Cohort 1-5: Baseline up to Day 7; Cohort 6: Baseline up to Day 8

  12. Part 2: Percentage of Participants Who Experience Clinically Significant Abnormal Changes in Safety EEG Measurements at Least Once Postdose

    Time frame: Baseline up to Day 18

  13. Part 1: Number of Participants With Treatment-emergent Suicidal Ideation or Suicidal Behavior as Measured Using Columbia-Suicide Severity Rating Scale (C-SSRS)

    Treatment-emergent suicidal ideation or behavior compared to baseline will be measured by an increase in suicidal ideation category (1-5 on the C-SSRS) or suicidal behavior category (6-10 on the C-SSRS) during treatment from the maximum suicidal ideation/behavior category at baseline, or any suicidal ideation/behavior during treatment if there is none at baseline. C-SSRS is used to assess whether participant experienced suicidal ideation (1: wish to be dead; 2: non-specific active suicidal thoughts; 3: active suicidal ideation with any methods (not plan) without intent to act; 4: active suicidal ideation with some intent to act, without specific plan; 5: active suicidal ideation with specific plan and intent) and suicidal behavior (6: actual attempt; 7: interrupted attempt; 8: aborted attempt; 9: preparatory acts or behavior; 10: suicidal behavior).

    Time frame: Cohort 1-5: Baseline up to Day 7; Cohort 6: Baseline up to Day 8

  14. Part 2: Number of Participants With Treatment-emergent Suicidal Ideation or Suicidal Behavior as Measured Using C-SSRS

    Treatment-emergent suicidal ideation or behavior compared to baseline will be measured by an increase in suicidal ideation category (1-5 on the C-SSRS) or suicidal behavior category (6-10 on the C-SSRS) during treatment from the maximum suicidal ideation/behavior category at baseline, or any suicidal ideation/behavior during treatment if there is none at baseline. C-SSRS is used to assess whether participant experienced suicidal ideation (1: wish to be dead; 2: non-specific active suicidal thoughts; 3: active suicidal ideation with any methods (not plan) without intent to act; 4: active suicidal ideation with some intent to act, without specific plan; 5: active suicidal ideation with specific plan and intent) and suicidal behavior (6: actual attempt; 7: interrupted attempt; 8: aborted attempt; 9: preparatory acts or behavior; 10: suicidal behavior).

    Time frame: Baseline up to Day 21

Secondary outcomes

  1. Cmax: Maximum Observed Plasma Concentration for TAK-653 on Day 1

    Time frame: Part 1 Cohort 1-5: Day 1 pre-dose and at multiple timepoints (up to 144 hours) post-dose; Part 1 Cohort 6: Day 1 pre-dose and at multiple timepoints (up to 168 hours) post-dose; Part 2: Day 1 pre-dose and at multiple timepoints (up to 120 hours) post-dose

  2. Part 2: Cmax: Maximum Observed Plasma Concentration for TAK-653 on Day 6

    Time frame: Day 6 pre-dose at multiple timepoints (up to 24 hours) post dose

  3. Part 2: Cmax,ss: Maximum Observed Plasma Concentration at Steady State for TAK-653

    Time frame: Day 18 pre-dose and at multiple time points (up to 24 hours) post dose

  4. Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-653 on Day 1

    Time frame: Part 1 Cohort 1-5: Day 1 pre-dose and at multiple timepoints (up to 144 hours) post-dose; Part 1 Cohort 6: Day 1 pre-dose and at multiple timepoints (up to 168 hours) post-dose; Part 2: Day 1 pre-dose and at multiple timepoints up to 120 hours) post-dose

  5. Part 2: Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-653 on Day 18

    Time frame: Day 18 pre-dose and at multiple time points (up to 24 hours) post dose

  6. AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-653

    Time frame: Part 1 Cohort 1-5: Day 1 pre-dose and at multiple timepoints (up to 144 hours) post-dose; Part 1 Cohort 6: Day 1 pre-dose and at multiple timepoints (up to 168 hours) post-dose; Part 2: Day 1 pre-dose and at multiple timepoints up to 120 hours) post-dose

  7. AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-653

    Time frame: Part 1 Cohort 1-5: Day 1 pre-dose and at multiple timepoints (up to 144 hours) post-dose; Part 1 Cohort 6: Day 1 pre-dose and at multiple timepoints (up to 168 hours) post-dose; Part 2: Day 1 pre-dose and at multiple timepoints up to 120 hours) post-dose

  8. Part 2: AUCτ: Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for TAK-653

    Time frame: Days 6 and 18 pre-dose and at multiple timepoints (up to 24 hours) post-dose

07

Results

Posted Feb 8, 2019

Participant flow

Participants took part in the study at 1 investigative site in United Kingdom from 26 August 2015 to 23 September 2017.

Part 1
Participant flow — Part 1
MilestonePart 1 Cohorts 1-6: Pooled PlaceboPart 1 Cohort 1: TAK-653 0.3 mgPart 1 Cohort 2: TAK-653 1 mgPart 1 Cohort 3: TAK-653 3 mg+TAK-653 3mgPart 1 Cohort 4: TAK-653 5 mgPart 1 Cohort 5: TAK-653 9 mgPart 1 Cohort 6: TAK-653 18 mgPart 2 Cohorts 1-5: Pooled PlaceboPart 2 Cohort 1: TAK-653 0.3 mgPart 2 Cohort 2: TAK-653 1 mgPart 2 Cohort 3: TAK-653 3 mgPart 2 Cohort 4: TAK-653 6 mgPart 2 Cohort 5: TAK-653 9 mg
Started12666666000000
Completed12666666000000
Not completed0000000000000
Part 2
Participant flow — Part 2
MilestonePart 1 Cohorts 1-6: Pooled PlaceboPart 1 Cohort 1: TAK-653 0.3 mgPart 1 Cohort 2: TAK-653 1 mgPart 1 Cohort 3: TAK-653 3 mg+TAK-653 3mgPart 1 Cohort 4: TAK-653 5 mgPart 1 Cohort 5: TAK-653 9 mgPart 1 Cohort 6: TAK-653 18 mgPart 2 Cohorts 1-5: Pooled PlaceboPart 2 Cohort 1: TAK-653 0.3 mgPart 2 Cohort 2: TAK-653 1 mgPart 2 Cohort 3: TAK-653 3 mgPart 2 Cohort 4: TAK-653 6 mgPart 2 Cohort 5: TAK-653 9 mg
Started00000001066666
Completed00000001066656
Not completed0000000000010
Withdrew: Adverse event0000000000010

Outcome measures

PrimaryPart 1: Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE)
Time frame:
Baseline up to Day 14
Reported as:
Number · percentage of participants
Part 1: Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE)
percentage of participantsPart 1 Cohorts 1-6: Pooled PlaceboPart 1 Cohort 1: TAK-653 0.3 mgPart 1 Cohort 2: TAK-653 1 mgPart 1 Cohort 3: TAK-653 3 mg+TAK-653 3mgPart 1 Cohort 4: TAK-653 5 mgPart 1 Cohort 5: TAK-653 9 mgPart 1 Cohort 6: TAK-653 18 mg
Part 1: Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE)41.766.766.750.083.333.333.3
PrimaryPart 2: Percentage of Participants Who Experience at Least One TEAE
Time frame:
Baseline up to Day 31
Reported as:
Number · percentage of participants
Part 2: Percentage of Participants Who Experience at Least One TEAE
percentage of participantsPart 2 Cohorts 1-5: Pooled PlaceboPart 2 Cohort 1: TAK-653 0.3 mgPart 2 Cohort 2: TAK-653 1 mgPart 2 Cohort 3: TAK-653 3 mgPart 2 Cohort 4: TAK-653 6 mgPart 2 Cohort 5: TAK-653 9 mg
Part 2: Percentage of Participants Who Experience at Least One TEAE50.050.050.0100.033.350.0
PrimaryPart 1: Percentage of Participants Who Discontinued the Treatment Due to an Adverse Event (AE)
Time frame:
Baseline up to Day 14
Reported as:
Number · percentage of participants
Part 1: Percentage of Participants Who Discontinued the Treatment Due to an Adverse Event (AE)
percentage of participantsPart 1 Cohorts 1-6: Pooled PlaceboPart 1 Cohort 1: TAK-653 0.3 mgPart 1 Cohort 2: TAK-653 1 mgPart 1 Cohort 3: TAK-653 3 mg+TAK-653 3mgPart 1 Cohort 4: TAK-653 5 mgPart 1 Cohort 5: TAK-653 9 mgPart 1 Cohort 6: TAK-653 18 mg
Part 1: Percentage of Participants Who Discontinued the Treatment Due to an Adverse Event (AE)0000000
PrimaryPart 2: Percentage of Participants Who Discontinued the Treatment Due to an AE
Time frame:
Baseline up to Day 31
Reported as:
Number · percentage of participants
Part 2: Percentage of Participants Who Discontinued the Treatment Due to an AE
percentage of participantsPart 2 Cohorts 1-5: Pooled PlaceboPart 2 Cohort 1: TAK-653 0.3 mgPart 2 Cohort 2: TAK-653 1 mgPart 2 Cohort 3: TAK-653 3 mgPart 2 Cohort 4: TAK-653 6 mgPart 2 Cohort 5: TAK-653 9 mg
Part 2: Percentage of Participants Who Discontinued the Treatment Due to an AE000016.70
PrimaryPart 1: Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Postdose
Time frame:
Cohort 1-5: Baseline up to Day 7; Cohort 6: Baseline up to Day 8
Reported as:
Number · percentage of participants
Part 1: Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Postdose
percentage of participantsPart 1 Cohorts 1-6: Pooled PlaceboPart 1 Cohort 1: TAK-653 0.3 mgPart 1 Cohort 2: TAK-653 1 mgPart 1 Cohort 3: TAK-653 3 mg+TAK-653 3mgPart 1 Cohort 4: TAK-653 5 mgPart 1 Cohort 5: TAK-653 9 mgPart 1 Cohort 6: TAK-653 18 mg
Part 1: Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Postdose016.7016.7000
PrimaryPart 2: Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Postdose
Time frame:
Baseline up to Day 8
Reported as:
Number · percentage of participants
Part 2: Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Postdose
percentage of participantsPart 2 Cohorts 1-5: Pooled PlaceboPart 2 Cohort 1: TAK-653 0.3 mgPart 2 Cohort 2: TAK-653 1 mgPart 2 Cohort 3: TAK-653 3 mgPart 2 Cohort 4: TAK-653 6 mgPart 2 Cohort 5: TAK-653 9 mg
Part 2: Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Postdose033.300016.7
PrimaryPart 1: Percentage of Participants Who Meet the Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Postdose
Time frame:
Cohort 1-5: Baseline up to Day 7; Cohort 6: Baseline up to Day 8
Reported as:
Number · percentage of participants
Part 1: Percentage of Participants Who Meet the Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Postdose
percentage of participantsPart 1 Cohorts 1-6: Pooled PlaceboPart 1 Cohort 1: TAK-653 0.3 mgPart 1 Cohort 2: TAK-653 1 mgPart 1 Cohort 3: TAK-653 3 mg+TAK-653 3mgPart 1 Cohort 4: TAK-653 5 mgPart 1 Cohort 5: TAK-653 9 mgPart 1 Cohort 6: TAK-653 18 mg
Part 1: Percentage of Participants Who Meet the Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Postdose75.050.0100.066.783.383.366.7
PrimaryPart 2: Percentage of Participants Who Meet the Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Postdose
Time frame:
Baseline up to Day 21
Reported as:
Number · percentage of participants
Part 2: Percentage of Participants Who Meet the Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Postdose
percentage of participantsPart 2 Cohorts 1-5: Pooled PlaceboPart 2 Cohort 1: TAK-653 0.3 mgPart 2 Cohort 2: TAK-653 1 mgPart 2 Cohort 3: TAK-653 3 mgPart 2 Cohort 4: TAK-653 6 mgPart 2 Cohort 5: TAK-653 9 mg
Part 2: Percentage of Participants Who Meet the Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Postdose90.0100.0100.0100.083.383.3
PrimaryPart 1: Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Electrocardiogram (ECG) at Least Once Postdose
Time frame:
Cohort 1-5: Baseline up to Day 7; Cohort 6: Baseline up to Day 8
Reported as:
Number · percentage of participants
Part 1: Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Electrocardiogram (ECG) at Least Once Postdose
percentage of participantsPart 1 Cohorts 1-6: Pooled PlaceboPart 1 Cohort 1: TAK-653 0.3 mgPart 1 Cohort 2: TAK-653 1 mgPart 1 Cohort 3: TAK-653 3 mg+TAK-653 3mgPart 1 Cohort 4: TAK-653 5 mgPart 1 Cohort 5: TAK-653 9 mgPart 1 Cohort 6: TAK-653 18 mg
Part 1: Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Electrocardiogram (ECG) at Least Once Postdose66.733.333.350.0033.350
PrimaryPart 2: Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety ECG at Least Once Postdose
Time frame:
Baseline up to Day 8
Reported as:
Number · percentage of participants
Part 2: Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety ECG at Least Once Postdose
percentage of participantsPart 2 Cohorts 1-5: Pooled PlaceboPart 2 Cohort 1: TAK-653 0.3 mgPart 2 Cohort 2: TAK-653 1 mgPart 2 Cohort 3: TAK-653 3 mgPart 2 Cohort 4: TAK-653 6 mgPart 2 Cohort 5: TAK-653 9 mg
Part 2: Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety ECG at Least Once Postdose40.050.050.016.750.016.7
PrimaryPart 1: Percentage of Participants Who Experience Clinically Significant Abnormal Changes in Safety Electroencephalogram (EEG) Measurements at Least Once Postdose
Time frame:
Cohort 1-5: Baseline up to Day 7; Cohort 6: Baseline up to Day 8
Reported as:
Number · percentage of participants
Part 1: Percentage of Participants Who Experience Clinically Significant Abnormal Changes in Safety Electroencephalogram (EEG) Measurements at Least Once Postdose
percentage of participantsPart 1 Cohorts 1-6: Pooled PlaceboPart 1 Cohort 1: TAK-653 0.3 mgPart 1 Cohort 2: TAK-653 1 mgPart 1 Cohort 3: TAK-653 3 mg+TAK-653 3mgPart 1 Cohort 4: TAK-653 5 mgPart 1 Cohort 5: TAK-653 9 mgPart 1 Cohort 6: TAK-653 18 mg
Part 1: Percentage of Participants Who Experience Clinically Significant Abnormal Changes in Safety Electroencephalogram (EEG) Measurements at Least Once Postdose0000000
PrimaryPart 2: Percentage of Participants Who Experience Clinically Significant Abnormal Changes in Safety EEG Measurements at Least Once Postdose
Time frame:
Baseline up to Day 18
Reported as:
Number · percentage of participants
Part 2: Percentage of Participants Who Experience Clinically Significant Abnormal Changes in Safety EEG Measurements at Least Once Postdose
percentage of participantsPart 2 Cohorts 1-5: Pooled PlaceboPart 2 Cohort 1: TAK-653 0.3 mgPart 2 Cohort 2: TAK-653 1 mgPart 2 Cohort 3: TAK-653 3 mgPart 2 Cohort 4: TAK-653 6 mgPart 2 Cohort 5: TAK-653 9 mg
Part 2: Percentage of Participants Who Experience Clinically Significant Abnormal Changes in Safety EEG Measurements at Least Once Postdose000000
PrimaryPart 1: Number of Participants With Treatment-emergent Suicidal Ideation or Suicidal Behavior as Measured Using Columbia-Suicide Severity Rating Scale (C-SSRS)

Treatment-emergent suicidal ideation or behavior compared to baseline will be measured by an increase in suicidal ideation category (1-5 on the C-SSRS) or suicidal behavior category (6-10 on the C-SSRS) during treatment from the maximum suicidal ideation/behavior category at baseline, or any suicidal ideation/behavior during treatment if there is none at baseline. C-SSRS is used to assess whether participant experienced suicidal ideation (1: wish to be dead; 2: non-specific active suicidal thoughts; 3: active suicidal ideation with any methods (not plan) without intent to act; 4: active suicidal ideation with some intent to act, without specific plan; 5: active suicidal ideation with specific plan and intent) and suicidal behavior (6: actual attempt; 7: interrupted attempt; 8: aborted attempt; 9: preparatory acts or behavior; 10: suicidal behavior).

Time frame:
Cohort 1-5: Baseline up to Day 7; Cohort 6: Baseline up to Day 8
Reported as:
Number · participants
Part 1: Number of Participants With Treatment-emergent Suicidal Ideation or Suicidal Behavior as Measured Using Columbia-Suicide Severity Rating Scale (C-SSRS)
participantsPart 1 Cohorts 1-6: Pooled PlaceboPart 1 Cohort 1: TAK-653 0.3 mgPart 1 Cohort 2: TAK-653 1 mgPart 1 Cohort 3: TAK-653 3 mg+TAK-653 3mgPart 1 Cohort 4: TAK-653 5 mgPart 1 Cohort 5: TAK-653 9 mgPart 1 Cohort 6: TAK-653 18 mg
Part 1: Number of Participants With Treatment-emergent Suicidal Ideation or Suicidal Behavior as Measured Using Columbia-Suicide Severity Rating Scale (C-SSRS)0000000
SecondaryCmax: Maximum Observed Plasma Concentration for TAK-653 on Day 1
Time frame:
Part 1 Cohort 1-5: Day 1 pre-dose and at multiple timepoints (up to 144 hours) post-dose; Part 1 Cohort 6: Day 1 pre-dose and at multiple timepoints (up to 168 hours) post-dose; Part 2: Day 1 pre-dose and at multiple timepoints (up to 120 hours) post-dose
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Cmax: Maximum Observed Plasma Concentration for TAK-653 on Day 1
nanogram per milliliter (ng/mL)Part 1 Cohort 1: TAK-653 0.3 mgPart 1 Cohort 2: TAK-653 1 mgPart 1 Cohort 3: TAK-653 3 mg+TAK-653 3mgPart 1 Cohort 4: TAK-653 5 mgPart 1 Cohort 5: TAK-653 9 mgPart 1 Cohort 6: TAK-653 18 mgPart 2 Cohort 1: TAK-653 0.3 mgPart 2 Cohort 2: TAK-653 1 mgPart 2 Cohort 3: TAK-653 3 mgPart 2 Cohort 4: TAK-653 6 mgPart 2 Cohort 5: TAK-653 9 mg
Cmax: Maximum Observed Plasma Concentration for TAK-653 on Day 13.5985 ± 1410.2220 ± 1526.9733 ± 1044.9430 ± 1368.8039 ± 16123.6462 ± 212.8630 ± 237.7786 ± 1228.0546 ± 2341.0028 ± 2476.0656 ± 27
SecondaryPart 2: Cmax: Maximum Observed Plasma Concentration for TAK-653 on Day 6
Time frame:
Day 6 pre-dose at multiple timepoints (up to 24 hours) post dose
Reported as:
Geometric mean · ng/mL
Part 2: Cmax: Maximum Observed Plasma Concentration for TAK-653 on Day 6
ng/mLPart 2 Cohort 1: TAK-653 0.3 mgPart 2 Cohort 2: TAK-653 1 mgPart 2 Cohort 3: TAK-653 3 mgPart 2 Cohort 4: TAK-653 6 mgPart 2 Cohort 5: TAK-653 9 mg
Part 2: Cmax: Maximum Observed Plasma Concentration for TAK-653 on Day 63.0485 ± 119.9202 ± 1633.4862 ± 3149.2842 ± 2178.8995 ± 32
SecondaryPart 2: Cmax,ss: Maximum Observed Plasma Concentration at Steady State for TAK-653
Time frame:
Day 18 pre-dose and at multiple time points (up to 24 hours) post dose
Reported as:
Geometric mean · ng/mL
Part 2: Cmax,ss: Maximum Observed Plasma Concentration at Steady State for TAK-653
ng/mLPart 2 Cohort 1: TAK-653 0.3 mgPart 2 Cohort 2: TAK-653 1 mgPart 2 Cohort 3: TAK-653 3 mgPart 2 Cohort 4: TAK-653 6 mgPart 2 Cohort 5: TAK-653 9 mg
Part 2: Cmax,ss: Maximum Observed Plasma Concentration at Steady State for TAK-6537.6221 ± 2923.9972 ± 3197.2781 ± 28140.4824 ± 37223.3637 ± 53
SecondaryTmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-653 on Day 1
Time frame:
Part 1 Cohort 1-5: Day 1 pre-dose and at multiple timepoints (up to 144 hours) post-dose; Part 1 Cohort 6: Day 1 pre-dose and at multiple timepoints (up to 168 hours) post-dose; Part 2: Day 1 pre-dose and at multiple timepoints up to 120 hours) post-dose
Reported as:
Median · hours
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-653 on Day 1
hoursPart 1 Cohort 1: TAK-653 0.3 mgPart 1 Cohort 2: TAK-653 1 mgPart 1 Cohort 3: TAK-653 3 mg+TAK-653 3mgPart 1 Cohort 4: TAK-653 5 mgPart 1 Cohort 5: TAK-653 9 mgPart 1 Cohort 6: TAK-653 18 mgPart 2 Cohort 1: TAK-653 0.3 mgPart 2 Cohort 2: TAK-653 1 mgPart 2 Cohort 3: TAK-653 3 mgPart 2 Cohort 4: TAK-653 6 mgPart 2 Cohort 5: TAK-653 9 mg
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-653 on Day 11.250 (1.00 to 1.50)2.500 (1.00 to 3.00)1.750 (1.00 to 10.07)2.750 (1.00 to 12.10)5.500 (1.50 to 12.00)5.050 (1.00 to 10.03)1.250 (1.00 to 8.13)4.000 (1.00 to 6.00)1.500 (1.00 to 6.00)5.000 (3.00 to 6.08)4.508 (1.00 to 12.12)
SecondaryPart 2: Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-653 on Day 18
Time frame:
Day 18 pre-dose and at multiple time points (up to 24 hours) post dose
Reported as:
Median · hours
Part 2: Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-653 on Day 18
hoursPart 2 Cohort 1: TAK-653 0.3 mgPart 2 Cohort 2: TAK-653 1 mgPart 2 Cohort 3: TAK-653 3 mgPart 2 Cohort 4: TAK-653 6 mgPart 2 Cohort 5: TAK-653 9 mg
Part 2: Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-653 on Day 182.500 (1.50 to 6.00)4.500 (2.00 to 12.00)4.000 (1.00 to 6.17)3.050 (1.00 to 10.00)3.000 (1.50 to 8.00)
SecondaryAUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-653
Time frame:
Part 1 Cohort 1-5: Day 1 pre-dose and at multiple timepoints (up to 144 hours) post-dose; Part 1 Cohort 6: Day 1 pre-dose and at multiple timepoints (up to 168 hours) post-dose; Part 2: Day 1 pre-dose and at multiple timepoints up to 120 hours) post-dose
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*hr/mL)
AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-653
nanogram*hour per milliliter (ng*hr/mL)Part 1 Cohort 1: TAK-653 0.3 mgPart 1 Cohort 2: TAK-653 1 mgPart 1 Cohort 3: TAK-653 3 mg+TAK-653 3mgPart 1 Cohort 4: TAK-653 5 mgPart 1 Cohort 5: TAK-653 9 mgPart 1 Cohort 6: TAK-653 18 mgPart 2 Cohort 1: TAK-653 0.3 mgPart 2 Cohort 2: TAK-653 1 mgPart 2 Cohort 3: TAK-653 3 mgPart 2 Cohort 4: TAK-653 6 mgPart 2 Cohort 5: TAK-653 9 mg
AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-653122.9927 ± 24539.0930 ± 341310.5344 ± 232247.5468 ± 294264.3612 ± 377755.4570 ± 34115.5869 ± 22382.2871 ± 281417.0994 ± 311810.5437 ± 424065.9350 ± 54
SecondaryAUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-653
Time frame:
Part 1 Cohort 1-5: Day 1 pre-dose and at multiple timepoints (up to 144 hours) post-dose; Part 1 Cohort 6: Day 1 pre-dose and at multiple timepoints (up to 168 hours) post-dose; Part 2: Day 1 pre-dose and at multiple timepoints up to 120 hours) post-dose
Reported as:
Geometric mean · ng*hr/mL
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-653
ng*hr/mLPart 1 Cohort 1: TAK-653 0.3 mgPart 1 Cohort 2: TAK-653 1 mgPart 1 Cohort 3: TAK-653 3 mg+TAK-653 3mgPart 1 Cohort 4: TAK-653 5 mgPart 1 Cohort 5: TAK-653 9 mgPart 1 Cohort 6: TAK-653 18 mgPart 2 Cohort 1: TAK-653 0.3 mgPart 2 Cohort 2: TAK-653 1 mgPart 2 Cohort 3: TAK-653 3 mgPart 2 Cohort 4: TAK-653 6 mgPart 2 Cohort 5: TAK-653 9 mg
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-653143.6521 ± 29596.5323 ± 431419.4306 ± 262536.8525 ± 354932.8519 ± 488413.1768 ± 40129.5373 ± 26448.9862 ± 361773.6365 ± 402027.7989 ± 565066.5536 ± 69
SecondaryPart 2: AUCτ: Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for TAK-653
Time frame:
Days 6 and 18 pre-dose and at multiple timepoints (up to 24 hours) post-dose
Reported as:
Geometric mean · ng*hr/mL
Part 2: AUCτ: Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for TAK-653
ng*hr/mLPart 2 Cohort 1: TAK-653 0.3 mgPart 2 Cohort 2: TAK-653 1 mgPart 2 Cohort 3: TAK-653 3 mgPart 2 Cohort 4: TAK-653 6 mgPart 2 Cohort 5: TAK-653 9 mg
Day 651.0759 ± 19159.9789 ± 16578.9157 ± 26778.2945 ± 131485.5059 ± 39
Day 18144.7834 ± 32477.3427 ± 381901.4065 ± 242747.5976 ± 424144.0176 ± 60
PrimaryPart 2: Number of Participants With Treatment-emergent Suicidal Ideation or Suicidal Behavior as Measured Using C-SSRS

Treatment-emergent suicidal ideation or behavior compared to baseline will be measured by an increase in suicidal ideation category (1-5 on the C-SSRS) or suicidal behavior category (6-10 on the C-SSRS) during treatment from the maximum suicidal ideation/behavior category at baseline, or any suicidal ideation/behavior during treatment if there is none at baseline. C-SSRS is used to assess whether participant experienced suicidal ideation (1: wish to be dead; 2: non-specific active suicidal thoughts; 3: active suicidal ideation with any methods (not plan) without intent to act; 4: active suicidal ideation with some intent to act, without specific plan; 5: active suicidal ideation with specific plan and intent) and suicidal behavior (6: actual attempt; 7: interrupted attempt; 8: aborted attempt; 9: preparatory acts or behavior; 10: suicidal behavior).

Time frame:
Baseline up to Day 21
Reported as:
Number · participants
Part 2: Number of Participants With Treatment-emergent Suicidal Ideation or Suicidal Behavior as Measured Using C-SSRS
participantsPart 2 Cohorts 1-5: Pooled PlaceboPart 2 Cohort 1: TAK-653 0.3 mgPart 2 Cohort 2: TAK-653 1 mgPart 2 Cohort 3: TAK-653 3 mgPart 2 Cohort 4: TAK-653 6 mgPart 2 Cohort 5: TAK-653 9 mg
Part 2: Number of Participants With Treatment-emergent Suicidal Ideation or Suicidal Behavior as Measured Using C-SSRS000000

Adverse events

Collected over Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 14 in Part 1 and Day 31 in Part 2. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1 Cohorts 1-6: Pooled Placebo0/12 (0%)0/12 (0%)5/12 (41.7%)
Part 1 Cohort 1: TAK-653 0.3 mg0/6 (0%)0/6 (0%)4/6 (66.7%)
Part 1 Cohort 2: TAK-653 1 mg0/6 (0%)0/6 (0%)4/6 (66.7%)
Part 1 Cohort 3: TAK-653 3 mg+TAK-653 3mg0/6 (0%)0/6 (0%)3/6 (50%)
Part 1 Cohort 4: TAK-653 5 mg0/6 (0%)0/6 (0%)5/6 (83.3%)
Part 1 Cohort 5: TAK-653 9 mg0/6 (0%)0/6 (0%)2/6 (33.3%)
Part 1 Cohort 6: TAK-653 18 mg0/6 (0%)0/6 (0%)2/6 (33.3%)
Part 2 Cohorts 1-5: Pooled Placebo0/10 (0%)0/10 (0%)5/10 (50%)
Part 2 Cohort 1: TAK-653 0.3 mg0/6 (0%)0/6 (0%)3/6 (50%)
Part 2 Cohort 2: TAK-653 1 mg0/6 (0%)0/6 (0%)3/6 (50%)
Part 2 Cohort 3: TAK-653 3 mg0/6 (0%)0/6 (0%)6/6 (100%)
Part 2 Cohort 4: TAK-653 6 mg0/6 (0%)0/6 (0%)2/6 (33.3%)
Part 2 Cohort 5: TAK-653 9 mg0/6 (0%)0/6 (0%)3/6 (50%)
Most frequent other events
Showing 10 of 35
Most frequent other events
EventPart 1 Cohorts 1-6: Pooled PlaceboPart 1 Cohort 1: TAK-653 0.3 mgPart 1 Cohort 2: TAK-653 1 mgPart 1 Cohort 3: TAK-653 3 mg+TAK-653 3mgPart 1 Cohort 4: TAK-653 5 mgPart 1 Cohort 5: TAK-653 9 mgPart 1 Cohort 6: TAK-653 18 mgPart 2 Cohorts 1-5: Pooled PlaceboPart 2 Cohort 1: TAK-653 0.3 mgPart 2 Cohort 2: TAK-653 1 mgPart 2 Cohort 3: TAK-653 3 mgPart 2 Cohort 4: TAK-653 6 mgPart 2 Cohort 5: TAK-653 9 mg
HeadacheNervous system disorders2/121/61/61/61/62/60/61/101/62/63/61/61/6
DizzinessNervous system disorders3/120/62/62/62/60/61/61/100/61/61/60/60/6
PresyncopeNervous system disorders0/120/60/61/60/60/60/60/100/60/62/60/60/6
PalpitationsCardiac disorders0/120/60/60/60/61/60/60/100/60/60/60/60/6
Sinus tachycardiaCardiac disorders0/120/60/60/61/60/60/60/100/60/60/60/60/6
NauseaGastrointestinal disorders1/120/60/60/60/60/60/61/100/60/61/60/61/6
Catheter site phlebitisGeneral disorders0/121/60/60/60/60/60/60/100/60/60/61/60/6
Catheter site related reactionGeneral disorders0/120/60/60/60/60/61/60/100/60/60/60/60/6
Influenza like illnessGeneral disorders0/120/60/60/60/60/61/60/100/60/60/60/60/6
Seasonal allergyImmune system disorders0/120/61/60/60/60/60/60/100/60/60/60/60/6

Baseline characteristics

The safety analysis set included all participants who received at least 1 dose of study drug.

Age, Categorical
Age, Categorical(Participants)Part 1 Cohorts 1-6: Pooled PlaceboPart 1 Cohort 1: TAK-653 0.3 mgPart 1 Cohort 2: TAK-653 1 mgPart 1 Cohort 3: TAK-653 3 mg+TAK-653 3mgPart 1 Cohort 4: TAK-653 5 mgPart 1 Cohort 5: TAK-653 9 mgPart 1 Cohort 6: TAK-653 18 mgPart 2 Cohorts 1-5: Pooled PlaceboPart 2 Cohort 1: TAK-653 0.3 mgPart 2 Cohort 2: TAK-653 1 mgPart 2 Cohort 3: TAK-653 3 mgPart 2 Cohort 4: TAK-653 6 mgPart 2 Cohort 5: TAK-653 9 mgTotal
<=18 years00000000000000
Between 18 and 65 years12666666106666688
>=65 years00000000000000
Sex: Female, Male
Sex: Female, Male(Participants)Part 1 Cohorts 1-6: Pooled PlaceboPart 1 Cohort 1: TAK-653 0.3 mgPart 1 Cohort 2: TAK-653 1 mgPart 1 Cohort 3: TAK-653 3 mg+TAK-653 3mgPart 1 Cohort 4: TAK-653 5 mgPart 1 Cohort 5: TAK-653 9 mgPart 1 Cohort 6: TAK-653 18 mgPart 2 Cohorts 1-5: Pooled PlaceboPart 2 Cohort 1: TAK-653 0.3 mgPart 2 Cohort 2: TAK-653 1 mgPart 2 Cohort 3: TAK-653 3 mgPart 2 Cohort 4: TAK-653 6 mgPart 2 Cohort 5: TAK-653 9 mgTotal
Female21100000000004
Male10556666106666684
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1 Cohorts 1-6: Pooled PlaceboPart 1 Cohort 1: TAK-653 0.3 mgPart 1 Cohort 2: TAK-653 1 mgPart 1 Cohort 3: TAK-653 3 mg+TAK-653 3mgPart 1 Cohort 4: TAK-653 5 mgPart 1 Cohort 5: TAK-653 9 mgPart 1 Cohort 6: TAK-653 18 mgPart 2 Cohorts 1-5: Pooled PlaceboPart 2 Cohort 1: TAK-653 0.3 mgPart 2 Cohort 2: TAK-653 1 mgPart 2 Cohort 3: TAK-653 3 mgPart 2 Cohort 4: TAK-653 6 mgPart 2 Cohort 5: TAK-653 9 mgTotal
Hispanic or Latino00100010000103
Not Hispanic or Latino12656665106665685
Unknown or Not Reported00000000000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1 Cohorts 1-6: Pooled PlaceboPart 1 Cohort 1: TAK-653 0.3 mgPart 1 Cohort 2: TAK-653 1 mgPart 1 Cohort 3: TAK-653 3 mg+TAK-653 3mgPart 1 Cohort 4: TAK-653 5 mgPart 1 Cohort 5: TAK-653 9 mgPart 1 Cohort 6: TAK-653 18 mgPart 2 Cohorts 1-5: Pooled PlaceboPart 2 Cohort 1: TAK-653 0.3 mgPart 2 Cohort 2: TAK-653 1 mgPart 2 Cohort 3: TAK-653 3 mgPart 2 Cohort 4: TAK-653 6 mgPart 2 Cohort 5: TAK-653 9 mgTotal
American Indian or Alaska Native00000000000000
Asian10000111000015
Native Hawaiian or Other Pacific Islander10000000000001
Black or African American10200100121008
White864664574456469
More than one race10000002100015
Unknown or Not Reported00000000000000
Region of Enrollment
Region of Enrollment(Participants)Part 1 Cohorts 1-6: Pooled PlaceboPart 1 Cohort 1: TAK-653 0.3 mgPart 1 Cohort 2: TAK-653 1 mgPart 1 Cohort 3: TAK-653 3 mg+TAK-653 3mgPart 1 Cohort 4: TAK-653 5 mgPart 1 Cohort 5: TAK-653 9 mgPart 1 Cohort 6: TAK-653 18 mgPart 2 Cohorts 1-5: Pooled PlaceboPart 2 Cohort 1: TAK-653 0.3 mgPart 2 Cohort 2: TAK-653 1 mgPart 2 Cohort 3: TAK-653 3 mgPart 2 Cohort 4: TAK-653 6 mgPart 2 Cohort 5: TAK-653 9 mgTotal
United Kingdom12666666106666688
Smoking Classification
Smoking Classification(Participants)Part 1 Cohorts 1-6: Pooled PlaceboPart 1 Cohort 1: TAK-653 0.3 mgPart 1 Cohort 2: TAK-653 1 mgPart 1 Cohort 3: TAK-653 3 mg+TAK-653 3mgPart 1 Cohort 4: TAK-653 5 mgPart 1 Cohort 5: TAK-653 9 mgPart 1 Cohort 6: TAK-653 18 mgPart 2 Cohorts 1-5: Pooled PlaceboPart 2 Cohort 1: TAK-653 0.3 mgPart 2 Cohort 2: TAK-653 1 mgPart 2 Cohort 3: TAK-653 3 mgPart 2 Cohort 4: TAK-653 6 mgPart 2 Cohort 5: TAK-653 9 mgTotal
Never smoked1045444464445462
Ex-smoker221222242221226
Female Reproductive Status
Female Reproductive Status(Participants)Part 1 Cohorts 1-6: Pooled PlaceboPart 1 Cohort 1: TAK-653 0.3 mgPart 1 Cohort 2: TAK-653 1 mgPart 1 Cohort 3: TAK-653 3 mg+TAK-653 3mgPart 1 Cohort 4: TAK-653 5 mgPart 1 Cohort 5: TAK-653 9 mgPart 1 Cohort 6: TAK-653 18 mgPart 2 Cohorts 1-5: Pooled PlaceboPart 2 Cohort 1: TAK-653 0.3 mgPart 2 Cohort 2: TAK-653 1 mgPart 2 Cohort 3: TAK-653 3 mgPart 2 Cohort 4: TAK-653 6 mgPart 2 Cohort 5: TAK-653 9 mgTotal
Surgically sterile10000000000001
Female of childbearing potential11100000000003
Caffeine Consumption
Caffeine Consumption(Participants)Part 1 Cohorts 1-6: Pooled PlaceboPart 1 Cohort 1: TAK-653 0.3 mgPart 1 Cohort 2: TAK-653 1 mgPart 1 Cohort 3: TAK-653 3 mg+TAK-653 3mgPart 1 Cohort 4: TAK-653 5 mgPart 1 Cohort 5: TAK-653 9 mgPart 1 Cohort 6: TAK-653 18 mgPart 2 Cohorts 1-5: Pooled PlaceboPart 2 Cohort 1: TAK-653 0.3 mgPart 2 Cohort 2: TAK-653 1 mgPart 2 Cohort 3: TAK-653 3 mgPart 2 Cohort 4: TAK-653 6 mgPart 2 Cohort 5: TAK-653 9 mgTotal
Had caffeine consumption863456594444466
Had no caffeine consumption403210112222222
08

Study locations

1 site
  • Hammersmith Medicines Research
    London, NW10 7EW, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available after applicable marketing approvals and commercial availability have been received, an opportunity for the primary publication of the research has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com/Approach for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2015 to primary completion in Sep 2017, 24 months.

Results were first posted in Feb 2019, 1 year 4 months after primary completion.

Of 28 industry-sponsored phase 1 interventional studies under Depressive Disorder, half reached primary completion within 3 months of starting (the median); a quarter within 1 and three quarters within 6. This study's 24 months is above that.

Counting every sponsor, half of 39 studies reached it within 5 months; a quarter within 1 and three quarters within 12.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2015
First posted
Sep 25, 2015
StartActual
Aug 26, 2015
Primary completionActual
Sep 11, 2017
CompletionActual
Sep 23, 2017
Results first posted
Feb 8, 2019
Last update
Mar 3, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02561156
Collaborators
Takeda
Responsible party
Sponsor
First posted
Sep 25, 2015
Start date
Aug 26, 2015
Primary completion
Sep 11, 2017
Completion
Sep 23, 2017
Results posted
Feb 8, 2019
Last update
Mar 3, 2021

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Osavampator

Start the discussion